-- 
Pluristem Jumps the Most in More Than Two Weeks on FDA Status

-- B y   G w e n   A c k e r m a n
-- 
2011-08-25T13:10:35Z

-- http://www.bloomberg.com/news/2011-08-25/pluristem-jumps-the-most-in-more-than-two-weeks-on-fda-status.html
Pluristem Therapeutics Inc. (PSTI)  jumped
the most in more than two weeks after it said its drug for
treating Buergerâ€™s Disease received orphan drug status from the
U.S. Food & Drug Administration.  The shares jumped 7.3 percent, their biggest intraday gain
since Aug. 8, to 9.838 shekels at 3:37 p.m. in  Tel Aviv .  To contact the reporters on this story:
Gwen Ackerman in  Jerusalem  at 
 gackerman@bloomberg.net .  To contact the editor responsible for this story:
Claudia Maedler at 
 cmaedler@bloomberg.net  